Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0002023658-25-000109
Filing Date
2025-11-10
Accepted
2025-11-10 16:27:09
Documents
69
Period of Report
2025-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q bcax-20250930.htm   iXBRL 10-Q 1999995
2 EX-31.1 exhibit311q3-25.htm EX-31.1 10500
3 EX-31.2 exhibit312q3-25.htm EX-31.2 10426
4 EX-32.1 exhibit321q3-25.htm EX-32.1 7614
10 bcax-20250930_g1.jpg GRAPHIC 138210
  Complete submission text file 0002023658-25-000109.txt   7001465

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bcax-20250930.xsd EX-101.SCH 38426
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT bcax-20250930_cal.xml EX-101.CAL 48855
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT bcax-20250930_def.xml EX-101.DEF 212100
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bcax-20250930_lab.xml EX-101.LAB 531636
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bcax-20250930_pre.xml EX-101.PRE 370031
72 EXTRACTED XBRL INSTANCE DOCUMENT bcax-20250930_htm.xml XML 634073
Mailing Address 116 HUNTINGTON AVENUE SUITE 703 BOSTON MA 02116
Business Address 116 HUNTINGTON AVENUE SUITE 703 BOSTON MA 02116 617-468-4219
Bicara Therapeutics Inc. (Filer) CIK: 0002023658 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42271 | Film No.: 251466626
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)